Evidence map›Paper›PMID 41497595›Full record

ArticlebioRxiv : the preprint server for biology2025

Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes.

Weijia Zhong, Carlo Scialò, Beatrice Gatta, Manon Häfliger, Noemi Leu, Flavio Lurati, Martina Peter, Nandini Ramesh, Bernd Roschitzki, Somanath Jagannath and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Weijia ZhongDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Carlo ScialòDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Beatrice GattaDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Manon HäfligerDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Noemi LeuDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Flavio LuratiDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Martina PeterDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Nandini RameshDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Bernd RoschitzkiFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.
Somanath JagannathDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Ruchi MangluniaDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.
Elena de CeccoInstitute of Neuropathology, University of Zurich, Zurich, Switzerland.
Su Min LimDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Oscar G WilkinsUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.
Adriano AguzziInstitute of Neuropathology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0344-6708
Michael WardNational Institutes of Health.ORCID 0000-0002-5296-8051
Pietro FrattaUCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID 0000-0002-7554-1632
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224.
Clotilde Lagier-TourenneDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Magdalini PolymenidouDepartment of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1271-9445

Funding

Targeting Dysregulated RNA Splicing in Neurodegenerative DiseasesRM1NS133601 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Paul Clark Blainey, Clotilde Lagier-Tourenne · 2023 to 2026
$7.4M
NINDS NIH HHS RM1 NS133601
6 · The paper itself

Abstract

Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) shows striking clinical and neuropathological heterogeneity, yet a systematic analysis of subtype-specific features and inter-patient variability was missing. We treated human neurons and neuron-like cells with 30 postmortem brain samples and quantified neoaggregate formation, loss of function and changes in the TDP-43 interactome to define determinants of seeding outcomes. Potent FTLD-TDP-A seeds drove a progressive collapse of physiological TDP-43 interactions accompanied by functional loss. Beyond the burden of pathological TDP-43, we identified the fibrillar core of the lysosomal protein TMEM106B as a critical pro-seeding factor. Transient lysosomal injury markedly enhanced neoaggregation and loss of function, likely by promoting fibril interactions with native TDP-43. Our work establishes a mechanistic link between TMEM106B and TDP-43 aggregation, identifies lysosomal escape as a key driver of pathology and introduces the strongest model yet for seeded TDP-43 aggregation and loss of function, to enable discovery of disease modifiers.

Indexed as

aggregationALS/FTDFTLD-TDP subtypesinteraction proteomicslysosomal escapeseedingTDP-43TMEM106

Identifiers

PMID41497595
PMCPMC12767511

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.